IR Biosciences — Investor Presentation (May 2006)
24 slides from IR Biosciences's investor presentation, May 31, 2006
Slide 1: ImmuneRegen BioSciences, Inc.
iK% Ic Bi: = acon) f ImmuneRegen HOSCIENCES, INC.
Slide 2: ImmuneRegen BioSciences, Inc.
[ ImmuneRegen BIOSCIENCES, INC.
Slide 3: Safe Harbor Statement
Statements contained in this presentation may contain information that includes or is based upon certain “forward-looking statements” relating to our business, future anticipated projected plans, performance and developments, as well as other statements relating to future operations and results. Any
Slide 4: Scientific Disclaimer
Scientific Disclaimer Statements contained in this presentation are based on the opinion of management. Although management believes these statements are supported by data and observations derived from scientific studies performed by the Company, all of the Company’s r esearch and development effort
Slide 5: IR BioSciences Holdings, Inc. overview and target markets
IR BioSciences Holdings, Inc. (OTCBB: ) A biopharmaceutical company engaged in research and development of applications for Sar 9 , Met (O 2 ) 11 - Substance P with potential applications in the following markets: IRBO Radiation-Induced Neutropenia and Thrombocytopenia Influenza and other Viral and
Slide 6: Key Facts
Russell Bedford Stefanou Mirchandani Auditor 12.8% Insider Ownership NA Institutional Ownership Shares 4 Full-time Employees 93,400,000 Fully Diluted Shares 78,319,254 Shares Outstanding (5/23/06) 1 December 31 $570,000 171,163 $27,846,251 $0.40 || $0.19 to 0.52 Scottsdale, AZ IRBO Fiscal Year Debt
Slide 7: Management team
Dr. Siegel has over a decade of experience providing scientific, clinical and regulatory assistance to life science client companies across the medical product spectrum, helping them meet business needs and FDA requirements from pre-clinical studies through the regulatory submission process and into
Slide 8: Advisory board
Commanding Officer of the Office of Naval Research Global, United States Navy, Medical Corps, (Ret.), Manager for Biosecurity and Biodefense, in the National Security Directorate at the Pacific Northwest National Laboratory former Under Secretary for Border and Transportation Security at the Departm
Slide 9: Research collaborators and contracted studies
TGen Drug Development Services (TD2 LLC) is contracted to perform anti-cancer research designed to assess preclinical efficacy (with the ability to expand to Phase 1 and Phase 2a clinical studies at the associated Mayo Clinic Scottsdale, MD Anderson Cancer Center and Arizona Cancer Center Tucson). C
Slide 10: Homspera, Radilex and Viprovex
The generic name Homspera was selected to refer to the Sar 9 , Met (O 2 ) 11 -Substance P peptide. Preferential conformation of Sar 9 , Met (O 2 ) 11 -Substance P (Homspera) in methanol Trade names for different formulations / indications Generic Name Homspera Research and development efforts are ce
Slide 11: Putative Mechanisms of Action
Anthrax : cytokine and apoptosis regulators Influenza : cytokines and macrophages TICs : cytokines and immunomodulators Viprovex Anti-Apoptosis (proteomics: peroxiredoxin protection enables ROS scavengering) Designed to protect / restore Immune System (neutropenia, thrombocytopenia, anemia) Design t
Slide 12: Indications
Treatment of pulmonary damage or distress caused by exposure to various biological and chemical agents: Anthrax Influenza (avian, equine, etc.) Chemically induced respiratory damage Viprovex Treatment of acute radiation exposure: Acute Radiation Syndrome (ARS) Neutropenia and Thrombocytopenia Design
Slide 13: Radilex: ARS
No toxicity witnessed in studies to date Potential of efficacy demonstrated in small animal models Particulate: Potassium iodide, DTPA, Prussian Blue Irradiation: Filgrastim (Neupogen ® ); 5-androstenediol (Neumune®; in development) : No approved standard Particulate : Deposition of radioactive part
Slide 14: Radilex study history
, September 2002, attempted to identify an LD50 value for subsequent standardization of exposure. , January 2003, administered Radilex via aerosol administration to determine efficacy, if any, by increasing survival time from a lethal dose of radiation. Observed that Radilex treated mice lived an av
Slide 15: Viprovex: Anthrax
No toxicity witnessed in studies to date Potential of efficacy demonstrated in protecting mice from inhaled anthrax ( Bacillus Anthracis) Antibiotics (ciprofloxacin, doxycyclin, penicillin) and supportive care Vaccines (BioPort) and anti-toxins (in development) : Viprovex: Anthrax Viprovex Treatment
Slide 16: Viprovex: Anthrax Studies
at their laboratory facilities located at Brooks City-Base in San Antonio, Texas with the cooperation of the U.S. Air Force School of Aerospace Medicine (USAFSAM). Studies are being conducted in hope of determining the efficacy of Viprovex in treating exposure to anthrax bacilli. The purpose of thes
Slide 17: Viprovex Potentially Activates Innate Immunity and Neuroprotection Genes
Real time PCR was used to examine cellular RNA for innate immunity and neuroprotection genes following Sar 9 , Met (O 2 ) 11 -Substance P treatment over a narrow micromolar range of concentrations: Viprovex Potentially Activates Innate Immunity and Neuroprotection Genes Defensins increase 50-5000 fo
Slide 18: Viprovex: Avian Influenza Potential
Potential of efficacy demonstrated in treating Hong Kong influenza virus in small animal models No toxicity witnessed in studies to date Tamiflu (oseltamivir, oral neuraminidase inhibitor) and Relenza (zanamivir, inhaled neuraminidase inhibitor) and Symmetrel (amantadine, inhibits viral entry/uncoat
Slide 19: Viprovex: Viral Studies
In October, 2003 using mice inoculated with the virus and treated with Viprovex. Results demonstrated that Viprovex in the mice inoculated with Hong Kong influenza virus and treated with Viprovex. Electron micrographs showed no virus particles in the Viprovex-treated animals in contrast to the contr
Slide 20: Hong Kong Influenza (Avian) and Viprovex
Hong Kong Influenza (Avian) and Viprovex
Slide 21: Development of Radilex and Viprovex
If the Company is capable of attaining treatment under the Animal Efficacy Rule ; however, there are no assurances of such occurring. Due to the lethal nature of the ailments that the Company is developing countermeasures against, . All of the Company’s r esearch efforts are at an . Development of R
Slide 22: Animal Efficacy Rule
“Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible” (Code of Federal Regulations, Title 21, Part 314, Subpart I) Animal Efficacy Rule Adopted by the FDA in 2002 Applies in situations where it would be unethical to conduct traditional Phase II and Phase III efficacy studie
Slide 23: Summary Financial Data
(3,376,889) Total stockholder's deficit 3,421,070 Total current liabilities 44,181 Total assets $ 23,161 Total current assets 44,181 Total liabilities and stockholders' deficit (Unaudited) 317,242 Options 14,765,569 Warrants — Preferred Stock 78,319,254 Common Stock 93,402,065 Total Summary Financia
Slide 24: IR BioSciences Holdings, Inc. contact details
IR BioSciences Holdings, Inc. 4021 N. 75th Street, Suite 201 Scottsdale, AZ 85251 480.922.3926 – Phone 480.922.4781 – Fax 866.922.3926 – Toll Free investors@immuneregen.com General Counsel Jeffrey R. Perry Law Office of Jeffrey R. Perry 11000 N. 77th Place, Suite 1053 Scottsdale, AZ 85260 480.368.54
IR Biosciences Holdings — Investor Presentation (May 2006) on 6ix